KRAS and metastatic colorectal cancer: In KRAS mutant colorectal cancer, Yang et al. revealed that cetuximab, an approved chemotherapeutic agent for metastatic colorectal cancer, promoted RSL3-induced ferroptosis by suppressing the p38/Nrf2/HO-1 signaling pathway [47].